Scarica l'app Stockscreener
0.00
100.00%
-9.81
Dopo l'orario di chiusura:
10.10
10.10
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALVR Giù?
Forum
Previsione
Precedente Chiudi:
$9.81
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$47.48M
Reddito:
-
Utile/perdita netta:
$-168.86M
Rapporto P/E:
0.00
EPS:
-1.68
Flusso di cassa netto:
$-125.29M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$24.15
Allovir Inc Stock (ALVR) Company Profile
Nome
Allovir Inc
Settore
Industria
Telefono
(617) 433-2605
Indirizzo
1100 WINTER STREET, WALTHAM
Confronta ALVR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
0.00 | 47.48M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-26 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| 2023-12-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-18 | Iniziato | BofA Securities | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2020-08-24 | Iniziato | JP Morgan | Overweight |
| 2020-08-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Allovir Inc Borsa (ALVR) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect - ACCESS Newswire
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities - TradingView
Millennium Management LLC Sells 251,018 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Wall Street Zen Upgrades Allovir (NASDAQ:KLRS) to Hold - MarketBeat
BNP Paribas Financial Markets Acquires New Holdings in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Allovir (NASDAQ:KLRS) Upgraded to “Hold” at Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Kalaris: Phase 1 Trial for TH103 Advances Following AlloVir Merger and Other Important Updates - TradingView
Allovir (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - Defense World
Deadline to Claim Your Payout from the AlloVir $ALVR Settlement Is in 3 Months - TradingView
AlloVir ($ALVR) Is Paying a Settlement to Investors — Here’s How to Get Your Share - TradingView
Kalaris Therapeutics, Inc. SEC 10-Q Report - TradingView
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Kalaris Eyes Breakthrough in AMD Treatment: Phase 1 Trial Progress and $101M War Chest Revealed in Q1 Earnings - Stock Titan
Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir LawsuitALVR - ACCESS Newswire
AlloVir, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsALVR - ACCESS Newswire
Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - ACCESS Newswire
Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALVR - ACCESS Newswire
Renaissance Technologies LLC Trims Stock Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
DEADLINE ALERT: Bernstein Liebhard LLP Reminds AlloVir, Inc. Investors of Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALVR - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Halper Sadeh LLP, AlloVir, Inc., Avid Bioservices, Inc., EMCORE Corporation - The Bradford Era
Halper Sadeh LLP, Aerovate Therapeutics, Inc., Staffing 360 Solutions, Inc., Allovir - The Bradford Era
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - marketscreener.com
William Blair Initiates Kalaris Therapeutics With Outperform Rating - MarketScreener
(ALVR) Technical Data - news.stocktradersdaily.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board chair - Investing.com India
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - The Manila Times
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Allovir Inc Azioni (ALVR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):